Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-056230
Filing Date
2025-04-21
Accepted
2025-04-21 14:29:50
Documents
22
Period of Report
2025-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A tngx-20250421.htm   iXBRL DEF 14A 1739175
2 GRAPHIC img161881702_0.jpg GRAPHIC 18128
3 GRAPHIC img161881702_1.jpg GRAPHIC 12976
4 GRAPHIC img161881702_2.jpg GRAPHIC 18128
5 GRAPHIC img161881702_3.jpg GRAPHIC 10618
6 GRAPHIC img161881702_4.jpg GRAPHIC 18128
7 GRAPHIC img161881702_5.jpg GRAPHIC 69377
8 GRAPHIC img161881702_6.jpg GRAPHIC 48235
9 GRAPHIC img161881702_7.jpg GRAPHIC 469376
10 GRAPHIC img161881702_8.jpg GRAPHIC 182495
  Complete submission text file 0000950170-25-056230.txt   5191492

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20250421.xsd EX-101.SCH 17815
24 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20250421_htm.xml XML 586269
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39485 | Film No.: 25852464
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)